Karen Anderson Sells 64,768 Shares of Centessa Pharmaceuticals (NASDAQ:CNTA) Stock

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) insider Karen Anderson sold 64,768 shares of Centessa Pharmaceuticals stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $28.21, for a total value of $1,827,105.28. Following the completion of the transaction, the insider owned 62,085 shares of the company’s stock, valued at approximately $1,751,417.85. This represents a 51.06% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Centessa Pharmaceuticals Trading Down 1.3%

Shares of NASDAQ CNTA opened at $28.34 on Friday. The stock has a market capitalization of $4.14 billion, a P/E ratio of -15.49 and a beta of 1.55. The company has a debt-to-equity ratio of 0.36, a current ratio of 10.56 and a quick ratio of 10.57. The business’s 50 day moving average is $25.17 and its two-hundred day moving average is $24.57. Centessa Pharmaceuticals PLC Sponsored ADR has a 1-year low of $9.60 and a 1-year high of $30.58.

Analysts Set New Price Targets

A number of equities analysts recently commented on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Centessa Pharmaceuticals in a research note on Wednesday, January 21st. Chardan Capital reissued a “buy” rating and issued a $30.00 price objective on shares of Centessa Pharmaceuticals in a research note on Friday, January 2nd. Wolfe Research started coverage on Centessa Pharmaceuticals in a research report on Tuesday, February 24th. They set an “outperform” rating and a $40.00 target price for the company. Piper Sandler reaffirmed an “overweight” rating on shares of Centessa Pharmaceuticals in a research note on Friday, January 16th. Finally, Oppenheimer increased their price target on Centessa Pharmaceuticals from $40.00 to $62.00 and gave the stock an “outperform” rating in a report on Wednesday, December 10th. Two equities research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $39.80.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. TD Waterhouse Canada Inc. bought a new stake in Centessa Pharmaceuticals during the 4th quarter valued at about $25,000. Caitong International Asset Management Co. Ltd bought a new position in Centessa Pharmaceuticals in the 4th quarter worth about $36,000. T. Rowe Price Investment Management Inc. increased its position in shares of Centessa Pharmaceuticals by 7,580.0% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 1,536 shares of the company’s stock worth $39,000 after acquiring an additional 1,516 shares during the period. Wells Fargo & Company MN raised its stake in shares of Centessa Pharmaceuticals by 42.4% during the fourth quarter. Wells Fargo & Company MN now owns 3,387 shares of the company’s stock valued at $85,000 after acquiring an additional 1,008 shares in the last quarter. Finally, Knott David M Jr bought a new stake in shares of Centessa Pharmaceuticals during the fourth quarter valued at approximately $100,000. Hedge funds and other institutional investors own 82.01% of the company’s stock.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.